Role of Nintedanib in COVID-19-Related Lung Fibrosis
In December 2020, Indonesia was introduced to the long Coronavirus disease 2019 (COVID-19) phenomenon. The Centers for Disease Control and Prevention (CDC) introduced the term "post-COVID condition" as a health problem that persists after four weeks from the first exposure to COVID-19. The...
Main Authors: | Alif Fathurrachman, Linda Andriani, Rouly Pasaribu, Sudarto Sudarto, Ahmad Rasyid, Zen Ahmad, Tommy Setiawan |
---|---|
Format: | Article |
Language: | English |
Published: |
Universitas Airlangga
2022-09-01
|
Series: | Jurnal Respirasi |
Subjects: | |
Online Access: | https://e-journal.unair.ac.id/JR/article/view/37540 |
Similar Items
-
Giant Pleural Hydatid Cyst: A Case Report
by: Sudarto Sudarto, et al.
Published: (2023-01-01) -
South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
by: Shaney L. Barratt, et al.
Published: (2018-12-01) -
Factors Affecting Best-Tolerated Dose of Pirfenidone in Patients with Fibrosing Interstitial Lung Disease
by: Neha P. Mandovra, et al.
Published: (2023-10-01) -
Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study
by: Yutaka Umemura, et al.
Published: (2021-07-01) -
Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
by: Moua T, et al.
Published: (2019-01-01)